Risk and Reward: Pharmacy Compounding of Clinical Materials
This article was originally published in The Gold Sheet
Executive Summary
More and more, drug makers are using pharmacies to compound their clinical materials quicker and cheaper than they themselves could manufacture them – but at what cost? The New England Compounding Center disaster and other incidents over the years make it clear that they must provide careful oversight to ensure quality.
You may also be interested in...
Manufacturers, Compounders Clash As FDA Prepares Final Offer On Office Compounding
Pharmaceutical manufacturers and compounders are in opposition over the US FDA’s plans to carve out a place for pharmacies that want to keep physicians’ offices stocked with small amounts of product. Who will the agency disappoint this time?
NECC Crisis Festered in Ambiguity That Reigns Over Compounding
As FDA, Congress and the courts stumbled, compounding pharmacies such as NECC took advantage of a gray area of the law. Legislators will get another try; one proposed subjecting such pharmacies to cGMP requirements.